Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial

BACKGROUND: Dose reduction of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukaemia (CML) with an optimal response to TKIs may support cost-effective medication use by maintaining therapeutic effectiveness while reducing adverse events and medication costs. As the choice for do...

Descripción completa

Detalles Bibliográficos
Autores principales: Djodikromo, Melissa F, Hermens, Rosella PMG, Bemt, Bart JF van den, Smit, Yolba, Govers, Tim M, Bekker, Charlotte L, Blijlevens, Nicole MA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007754/
https://www.ncbi.nlm.nih.gov/pubmed/36899295
http://dx.doi.org/10.1186/s12885-023-10697-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007754/
https://www.ncbi.nlm.nih.gov/pubmed/36899295
http://dx.doi.org/10.1186/s12885-023-10697-6

Ejemplares similares